Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This shows that the convection enhanced delivery methods have improved to the point where they can get the drug, on average, to over 75% of the tumor, and it should only get better with more experience. They compare this to the PRECISE trial where the drug only got to about 20% of the tumor.
Here is a link to the poster.
There is a phase 2 clinical trial going on now for this treatment, MDNA55, in patients with recurrent or progressive GBM.
Disclaimer: Medicenna Therapeutics is a sponsor of the Musella Foundation
Posted on: 11/22/2017
Click HERE to return to brain tumor news headlines